AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00275028 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Fallopian Tube Cancer
Primary Peritoneal Serous Adenocarcinoma
Recurrent Ovarian Epithelial Cancer
Stage I Ovarian Epithelial Cancer
Stage II Ovarian Epithelial Cancer

Interventions

DRUG: cediranib maleate

Sponsor

National Cancer Institute (NCI)